A Phase 1 interventional study of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Apellis Pharmaceuticals, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-08.
Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Hemoglobinuria, Paroxysmal with a site in United States — 10 open to participants now, 16 under way, 4 of them phase 3. Hemoglobinuria, Paroxysmal · United States.
Among the 68 studies in Hemoglobinuria, Paroxysmal with a site in United States, this one is the 48th largest by enrollment of the 54 interventional ones that give a count, is the only one that started in 2015, is one of 5 in phase 1, and was the 34th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →10 of the 68 studies in Hemoglobinuria, Paroxysmal with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Brazil, Colombia and 3 more countries
Ages 2–18
Alexion Pharmaceuticals, Inc. · Sites in United States, Australia, France and 4 more countries
Women only
Novartis Pharmaceuticals · Sites in United States
Ages 18–99
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages 0–75
International PNH Interest Group · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 53 across the 54 interventional studies, 75 across the 13 observational. Of the 50 that completed or were terminated, 26 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 68 have an industry lead sponsor. The 10 most frequent:
This study is registered under Apellis Pharmaceuticals, Inc., one of the names counted as Biogen. Under that name alone:
Apellis Pharmaceuticals, Inc. is the lead sponsor of 28 studies on the registry; 3 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Biogen has 6 studies filed under Hemoglobinuria, Paroxysmal — fewer than ten, so there is no comparison to draw.
3 of the studies in Hemoglobinuria, Paroxysmal with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04432584Phase 3Hoffmann-La RocheA Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors | 2027-04-18 |
| NCT04747613Phase 3Novartis PharmaceuticalsLong-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | 2027-10-18 |
| NCT03520647National Heart, Lung, and Blood Institute (NHLBI)Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 68 studies in Hemoglobinuria, Paroxysmal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will be the initial exploration of pegcetacoplan in patients with PNH. The assessments of the safety, tolerability, PK, and PD following administration of single and multiples doses of pegcetacoplan will guide decisions to further develop the drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
First Dose 25mg, Repeated Dose 5 mg/day
Drug: Pegcetacoplan
First Dose 50 mg, Repeated Dose 30 mg/day
Drug: Pegcetacoplan
Repeated Dose 180 mg/day
Drug: Pegcetacoplan
Repeated Dose 270 mg/day
Drug: Pegcetacoplan
Complement (C3) Inhibitor
Also known as: APL-2
Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Including by Severity, During Single-dose Phase
TEAEs were defined as AEs that developed or worsened after first dose of study drug (Day 1), and up to 30 days after last dose of study drug. The Investigator assessed AEs for severity and relatedness to study drug. AEs were graded according to the Common Terminology Criteria for Adverse Events (CTCAE, v4.03) based on: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death related to AE.
Time frame: From single dose of study drug (Day 1) up to 30 days
Number of Subjects With TEAEs, Including by Severity, During Multiple-dose Phase
TEAEs were defined as AEs that developed or worsened after first dose of study drug (Day 1), and up to 30 days after last dose of study drug. The Investigator assessed AEs for severity and relatedness to study drug. AEs were graded according to CTCAE, v4.03 based on: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death related to AE.
Time frame: From first dose of study drug up to 30 days after last dose of study drug (Cohorts 1-3: up to 58 days; Cohort 4: up to 759 days).
Area Under the Curve (AUC) From Time 0 to the Last Measurable Concentration (AUC0-t) Over the Multiple Dosing Phase for Cohort 4
Assessment of AUC0-t of pegcetacoplan over the multiple dosing phase, estimated using a non-compartmental approach and calculated by the linear-log trapezoidal method. Pegcetacoplan pharmacokinetic (PK) parameters were summarized for Cohort 4 only.
Time frame: Blood samples for PK assessment were collected pre-dose and 4 hours post dose on Day 1 and pre-dose (trough) on Day 2 and up to Day 785.
Maximum Pre-dose Serum Concentration (Ctrough,Max) Over the Multiple Dosing Phase for Cohort 4
Assessment of Ctrough,max of pegcetacoplan over the multiple dosing phase, estimated using a non-compartmental approach. Pegcetacoplan PK parameters were summarized for Cohort 4 only. Ctrough,max was calculated for both 270 mg/day and 360 mg/day where subjects received both doses. Note: 1 subject in Cohort 4 who was receiving 360 mg/day was granted Sponsor and institutional review board approval to increase the dose further to the equivalent of 440 mg/day and Ctrough,max is also reported for this dose.
Time frame: Blood samples for PK assessment were collected pre-dose and 4 hours post dose on Day 1 and pre-dose (trough) on Day 2 and up to Day 785.
Paroxysmal nocturnal hemoglobinuria (PNH) subjects who were still anemic during treatment with eculizumab (Soliris®) were enrolled in this Phase 1, open-label, single- and multiple-ascending dose study to receive treatment with pegcetacoplan (APL-2) as an add-on to standard of care treatment. The study was conducted at 7 sites in the United States.
| Milestone | Cohort 1 Single- and Multiple-dose Phase | Cohort 2 Single- and Multiple-dose Phase | Cohort 2 Single-dose Phase, Then Cohorts 2, 3, and 4 Multiple-dose Phase | Cohorts 3 and 4 Multiple-dose Phase | Cohort 4 Multiple-dose Phase |
|---|---|---|---|---|---|
| Started | 2 | 1 | 1 | 1 | 4 |
| Completed | 0 | 1 | 0 | 1 | 3 |
| Not completed | 2 | 0 | 1 | 0 | 1 |
| Withdrew: Death (after completing single-dose phase) | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject (during multiple-dose phase) | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy (during multiple-dose phase) | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Major intercurrent illness (during multiple-dose phase) | 0 | 0 | 0 | 0 | 1 |
TEAEs were defined as AEs that developed or worsened after first dose of study drug (Day 1), and up to 30 days after last dose of study drug. The Investigator assessed AEs for severity and relatedness to study drug. AEs were graded according to the Common Terminology Criteria for Adverse Events (CTCAE, v4.03) based on: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death related to AE.
| Participants | Cohort 1 Single-dose Phase | Cohort 2 Single-dose Phase |
|---|---|---|
| Any TEAE | 1 | 2 |
| TEAE at least possibly related to study drug | 0 | 1 |
| Serious TEAE | 0 | 0 |
| TEAE leading to study drug discontinuation | 0 | 0 |
| TEAE leading to death | 0 | 0 |
| Maximum severity of all TEAEs: mild | 0 | 1 |
| Maximum severity of all TEAEs: moderate | 1 | 1 |
| Maximum severity of all TEAEs: severe | 0 | 0 |
TEAEs were defined as AEs that developed or worsened after first dose of study drug (Day 1), and up to 30 days after last dose of study drug. The Investigator assessed AEs for severity and relatedness to study drug. AEs were graded according to CTCAE, v4.03 based on: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death related to AE.
| Participants | Cohort 1 Multiple-dose Phase | Cohort 2 Multiple-dose Phase | Cohort 3 Multiple-dose Phase | Cohort 4 Multiple-dose Phase |
|---|---|---|---|---|
| Any TEAE | 1 | 2 | 1 | 6 |
| TEAE at least possibly related to study drug | 0 | 1 | 1 | 4 |
| Serious TEAE | 0 | 0 | 0 | 2 |
| TEAE leading to study drug discontinuation | 1 | 0 | 0 | 0 |
| TEAE leading to death | 0 | 0 | 0 | 0 |
| Maximum severity of all TEAEs: mild | 0 | 0 | 1 | 0 |
| Maximum severity of all TEAEs: moderate | 0 | 2 | 0 | 2 |
| Maximum severity of all TEAEs: severe | 1 | 0 | 0 | 4 |
| Maximum severity of all TEAEs: life-threatening | 0 | 0 | 0 | 0 |
Assessment of AUC0-t of pegcetacoplan over the multiple dosing phase, estimated using a non-compartmental approach and calculated by the linear-log trapezoidal method. Pegcetacoplan pharmacokinetic (PK) parameters were summarized for Cohort 4 only.
| micrograms*hour/milliliter (μg*hour/mL) | Cohort 4 Multiple-dose Phase |
|---|---|
| Area Under the Curve (AUC) From Time 0 to the Last Measurable Concentration (AUC0-t) Over the Multiple Dosing Phase for Cohort 4 | 6,500,000 ± 3,990,000 |
Assessment of Ctrough,max of pegcetacoplan over the multiple dosing phase, estimated using a non-compartmental approach. Pegcetacoplan PK parameters were summarized for Cohort 4 only. Ctrough,max was calculated for both 270 mg/day and 360 mg/day where subjects received both doses. Note: 1 subject in Cohort 4 who was receiving 360 mg/day was granted Sponsor and institutional review board approval to increase the dose further to the equivalent of 440 mg/day and Ctrough,max is also reported for this dose.
| μg/mL | Cohort 4 Multiple-dose Phase |
|---|---|
| 270 mg Dose | 627 ± 207 |
| 360 mg Dose | 543 ± 192 |
| 440 mg Dose | 624 ± NA |
Collected over TEAE data is reported from first dose of study drug up to 30 days after last dose of study drug (Cohorts 1 and 2, single-dose phase: up to 30 days; Cohorts 1-3, multiple-dose phase: up to 58 days; Cohort 4, multiple-dose phase: up to 759 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 Single-dose Phase | 1/2 (50%) | 0/2 (0%) | 1/2 (50%) |
| Cohort 2 Single-dose Phase | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Cohort 1 Multiple-dose Phase | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Cohort 2 Multiple-dose Phase | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Cohort 3 Multiple-dose Phase | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Cohort 4 Multiple-dose Phase | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Event | Cohort 1 Single-dose Phase | Cohort 2 Single-dose Phase | Cohort 1 Multiple-dose Phase | Cohort 2 Multiple-dose Phase | Cohort 3 Multiple-dose Phase | Cohort 4 Multiple-dose Phase |
|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/2 | 0/2 | 0/1 | 0/2 | 0/2 | 1/6 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 0/2 | 0/2 | 0/1 | 0/2 | 0/2 | 1/6 |
| PancreatitisGastrointestinal disorders | 0/2 | 0/2 | 0/1 | 0/2 | 0/2 | 1/6 |
| Portal vein thrombosisHepatobiliary disorders | 0/2 | 0/2 | 0/1 | 0/2 | 0/2 | 1/6 |
| SepsisInfections and infestations | 0/2 | 0/2 | 0/1 | 0/2 | 0/2 | 1/6 |
| Alanine aminotransferase increasedInvestigations | 0/2 | 0/2 | 0/1 | 0/2 | 0/2 | 1/6 |
| Aspartate aminotransferase increasedInvestigations | 0/2 | 0/2 | 0/1 | 0/2 | 0/2 | 1/6 |
| Event | Cohort 1 Single-dose Phase | Cohort 2 Single-dose Phase | Cohort 1 Multiple-dose Phase | Cohort 2 Multiple-dose Phase | Cohort 3 Multiple-dose Phase | Cohort 4 Multiple-dose Phase |
|---|---|---|---|---|---|---|
| Injection-site bruisingGeneral disorders | 0/2 | 0/2 | 0/1 | 2/2 | 1/2 | 4/6 |
| Non-cardiac chest painGeneral disorders | 0/2 | 0/2 | 1/1 | 0/2 | 0/2 | 0/6 |
| Vitamin B12 decreasedInvestigations | 0/2 | 0/2 | 1/1 | 0/2 | 0/2 | 0/6 |
| HeadacheNervous system disorders | 0/2 | 0/2 | 1/1 | 0/2 | 0/2 | 5/6 |
| DysaesthesiaNervous system disorders | 0/2 | 0/2 | 1/1 | 0/2 | 0/2 | 0/6 |
| AnxietyPsychiatric disorders | 0/2 | 0/2 | 1/1 | 1/2 | 0/2 | 0/6 |
| DepressionPsychiatric disorders | 0/2 | 0/2 | 1/1 | 0/2 | 0/2 | 0/6 |
| Injection-site painGeneral disorders | 0/2 | 0/2 | 0/1 | 0/2 | 0/2 | 4/6 |
| NauseaGastrointestinal disorders | 1/2 | 0/2 | 0/1 | 1/2 | 0/2 | 1/6 |
| DiarrhoeaGastrointestinal disorders | 1/2 | 0/2 | 0/1 | 1/2 | 0/2 | 1/6 |
The safety population included all enrolled subjects who received at least 1 dose of study drug. Total unique participants = 9. Subjects could participate in more than 1 cohort. 1 subject participated in Cohorts 2, 3 and 4, and 1 subject participated in Cohorts 3 and 4.
| Age, Categorical(Participants) | Cohort 1 Single- and Multiple-dose Phase | Cohort 2 Single- and Multiple-dose Phase | Cohort 2 Single-dose Phase, Then Cohorts 2, 3, and 4 Multiple-dose Phase | Cohorts 3 and 4 Multiple-dose Phase | Cohort 4 Multiple-dose Phase | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 1 | 1 | 1 | 4 | 8 |
| >=65 years | 1 | 0 | 0 | 0 | 0 | 1 |
| Sex: Female, Male(Participants) | Cohort 1 Single- and Multiple-dose Phase | Cohort 2 Single- and Multiple-dose Phase | Cohort 2 Single-dose Phase, Then Cohorts 2, 3, and 4 Multiple-dose Phase | Cohorts 3 and 4 Multiple-dose Phase | Cohort 4 Multiple-dose Phase | Total |
|---|---|---|---|---|---|---|
| Female | 2 | 0 | 1 | 1 | 4 | 8 |
| Male | 0 | 1 | 0 | 0 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 Single- and Multiple-dose Phase | Cohort 2 Single- and Multiple-dose Phase | Cohort 2 Single-dose Phase, Then Cohorts 2, 3, and 4 Multiple-dose Phase | Cohorts 3 and 4 Multiple-dose Phase | Cohort 4 Multiple-dose Phase | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 2 | 1 | 1 | 0 | 4 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1 Single- and Multiple-dose Phase | Cohort 2 Single- and Multiple-dose Phase | Cohort 2 Single-dose Phase, Then Cohorts 2, 3, and 4 Multiple-dose Phase | Cohorts 3 and 4 Multiple-dose Phase | Cohort 4 Multiple-dose Phase | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 1 | 1 |
| White | 2 | 1 | 1 | 1 | 3 | 8 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Cohort 1 Single- and Multiple-dose Phase | Cohort 2 Single- and Multiple-dose Phase | Cohort 2 Single-dose Phase, Then Cohorts 2, 3, and 4 Multiple-dose Phase | Cohorts 3 and 4 Multiple-dose Phase | Cohort 4 Multiple-dose Phase | Total |
|---|---|---|---|---|---|---|
| United States | 2 | 1 | 1 | 1 | 4 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2015 to primary completion in Oct 2018, 43 months.
Results were first posted in Jan 2021, 2 years 2 months after primary completion.
Of 19 phase 1 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's 43 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegcetacoplan
Apellis Pharmaceuticals, Inc. →